Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 206

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 206
---
         |         |     |                |           |
| Marketable Securities:                     |     |         |           |     |         |   |     |         |         |     |                |           |
| United States Treasury Bonds               |     | $       | 2,887,215 |     | $       | — |     | $       |       — |     | $              | 2,887,215 |
| Total Assets                               |     | $       | 2,887,215 |     | $       | — |     | $       |       — |     | $              | 2,887,215 |
| Liabilities                                |     |         |           |     |         |   |     |         |         |     |                |           |
| Derivative Liability - Warrants            |     | $       |         — |     | $       | — |     | $       | 410,660 |     | $              |   410,660 |
| Derivative Liability - Accelerated feature |     |         |         — |     |         | — |     |         |   3,852 |     |                |     3,852 |
| Total Liabilities                          |     | $       |         — |     | $       | — |     | $       | 414,512 |     | $              |   414,512 |

| F-30 |

During the year ended December 31, 2022, the Company had non-derivative warrant liabilities that were measured at fair value on a recurring basis. Each of these fair value measurements was considered to be a Level 3 measurement by the Company as they used significant unobservable inputs, such as the Company’s pre-IPO stock price, probability of event occurrence and other management estimates. The key inputs for each of these warrant liabilities were as follows:

Schedule of Key Inputs of Warrant Liabilities

| Warrant Liability – Series A Preferred Stock Obligation                                                            |     | December 31, 2021 |                        |   |     | Reclassification Date |               |   |
|:-------------------------------------------------------------------------------------------------------------------|:----|:------------------|-----------------------:|:--|:----|:----------------------|--------------:|:--|
| Estimated fair value of Company’s stock                                                                            |     | $                 |                  40.00 |   |     | $                     |         32.50 |   |
| Exercise price (based on estimated IPO or Listing terms